We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
Read MoreHide Full Article
Key Takeaways
WST's HVP Components sales rose 18.4% organically, supported by biologics, GLP-1 elastomers and Annex 1.
West's adjusted operating margin rose 230 basis points to 22.6% on HVP mix, pricing and leverage.
WST trades at 37.1X forward earnings, well above its sub-industry's 18.0X multiple.
West Pharmaceutical Services, Inc. (WST - Free Report) is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share.
The question is whether those gains justify a valuation well above industry levels. WST’s growth drivers remain attractive, but the premium multiple leaves less room for operational missteps.
WST's HVP Growth Supports the Bull Case
HVP Components generated $424.1 million in second-quarter sales, or 49% of total company revenues, and grew 18.4% organically. Biologics, GLP-1 elastomers and customer upgrades tied to Annex 1 requirements supported the increase.
West Pharmaceutical Services, Inc. Revenue (Quarterly)
Management expects Annex 1 and broader HVP conversion to add about 200 basis points to 2026 revenue growth. West has just under 800 related projects in hand, up 50% from a year earlier.
Eli Lilly and Company (LLY - Free Report) is advancing retatrutide in late-stage obesity and diabetes development, underscoring continued innovation in metabolic therapies. Novo Nordisk A/S (NVO - Free Report) remains focused on obesity and diabetes, including newer Wegovy formats, reinforcing the breadth of the GLP-1 market.
West's Margins Improve as Mix Shifts Higher
Second-quarter gross margin expanded 200 basis points year over year to 37.7%. Adjusted operating margin increased 230 basis points to 22.6%, helped by favorable HVP mix, pricing and operating leverage.
Management now expects more than 200 basis points of full-year operating-margin expansion compared with 2025. The richer product mix is helping offset inflationary pressure from oil and other commodities.
WST's Valuation Leaves Less Room for Error
WST trades at 37.1X forward 12-month earnings, versus 18.0X for its Zacks sub-industry and 20.7X for the S&P 500. That is a sizable relative premium.
The multiple is below WST’s five-year median of 39.1X, so the stock is not expensive relative to its own recent history. Still, investors are paying substantially more than peer and market benchmarks for the company’s expected growth.
Image Source: Zacks Investment Research
West Faces Execution and Cost Risks
West Vantage grew just 0.8% organically in the second quarter. Cyber-related production downtime reduced the segment’s gross margin, and management expects the third quarter to mark the trough before improvement later in the year.
Standard Products grew only 0.7% organically. Commodity inflation and the July 1 transfer of SmartDose 3.5mL manufacturing and supply rights add further variables as West works through portfolio and operating changes.
WST's Balance Sheet Adds Flexibility
West ended June with $435.8 million in cash and cash equivalents against $202.9 million of total debt. That balance sheet provides capacity to support HVP investments while continuing shareholder returns.
The company repurchased 1.8 million shares for $454.3 million in the first half of 2026 under its $1 billion authorization. First-half capital spending declined to $85.9 million from $146.5 million a year earlier, while the quarterly dividend remains 22 cents per share.
Wrapping Up
The operating case is improving, but valuation and execution risk make the entry decision less straightforward. HVP growth, margin expansion and balance sheet flexibility support the long-term thesis, while the premium multiple argues for price discipline.
View the Zacks #1 Rank List
Image: Bigstock
Should Investors Buy WST as HVP Growth Meets a Premium Valuation?
Key Takeaways
West Pharmaceutical Services, Inc. (WST - Free Report) is delivering faster High-Value Product (HVP) growth, wider margins and higher 2026 earnings expectations. Second-quarter organic sales rose 12.7%, while adjusted earnings increased 28.8% to $2.37 per share.
The question is whether those gains justify a valuation well above industry levels. WST’s growth drivers remain attractive, but the premium multiple leaves less room for operational missteps.
WST's HVP Growth Supports the Bull Case
HVP Components generated $424.1 million in second-quarter sales, or 49% of total company revenues, and grew 18.4% organically. Biologics, GLP-1 elastomers and customer upgrades tied to Annex 1 requirements supported the increase.
West Pharmaceutical Services, Inc. Revenue (Quarterly)
West Pharmaceutical Services, Inc. revenue-quarterly | West Pharmaceutical Services, Inc. Quote
Management expects Annex 1 and broader HVP conversion to add about 200 basis points to 2026 revenue growth. West has just under 800 related projects in hand, up 50% from a year earlier.
Eli Lilly and Company (LLY - Free Report) is advancing retatrutide in late-stage obesity and diabetes development, underscoring continued innovation in metabolic therapies. Novo Nordisk A/S (NVO - Free Report) remains focused on obesity and diabetes, including newer Wegovy formats, reinforcing the breadth of the GLP-1 market.
West's Margins Improve as Mix Shifts Higher
Second-quarter gross margin expanded 200 basis points year over year to 37.7%. Adjusted operating margin increased 230 basis points to 22.6%, helped by favorable HVP mix, pricing and operating leverage.
Management now expects more than 200 basis points of full-year operating-margin expansion compared with 2025. The richer product mix is helping offset inflationary pressure from oil and other commodities.
WST's Valuation Leaves Less Room for Error
WST trades at 37.1X forward 12-month earnings, versus 18.0X for its Zacks sub-industry and 20.7X for the S&P 500. That is a sizable relative premium.
The multiple is below WST’s five-year median of 39.1X, so the stock is not expensive relative to its own recent history. Still, investors are paying substantially more than peer and market benchmarks for the company’s expected growth.
Image Source: Zacks Investment Research
West Faces Execution and Cost Risks
West Vantage grew just 0.8% organically in the second quarter. Cyber-related production downtime reduced the segment’s gross margin, and management expects the third quarter to mark the trough before improvement later in the year.
Standard Products grew only 0.7% organically. Commodity inflation and the July 1 transfer of SmartDose 3.5mL manufacturing and supply rights add further variables as West works through portfolio and operating changes.
WST's Balance Sheet Adds Flexibility
West ended June with $435.8 million in cash and cash equivalents against $202.9 million of total debt. That balance sheet provides capacity to support HVP investments while continuing shareholder returns.
The company repurchased 1.8 million shares for $454.3 million in the first half of 2026 under its $1 billion authorization. First-half capital spending declined to $85.9 million from $146.5 million a year earlier, while the quarterly dividend remains 22 cents per share.
Wrapping Up
The operating case is improving, but valuation and execution risk make the entry decision less straightforward. HVP growth, margin expansion and balance sheet flexibility support the long-term thesis, while the premium multiple argues for price discipline.
Currently, West carries a Zacks Rank #3 (Hold). Likewise, Eli Lilly and Novo Nordisk also carry a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.